J Korean Diabetes.  2013 Sep;14(3):128-132. 10.4093/jkd.2013.14.3.128.

DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes

Affiliations
  • 1Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. merongfox@gmail.com

Abstract

Dipeptidylpeptidase-4 (DPP-4) inhibitors are new glucose-lowering agents with mechanisms that differ from those of previous oral hypoglycemic agents (OHAs). DPP-4 inhibitors have shown a continuous glucose lowering effect (> 0.5%) when used in monotherapy as well as when used in combination with metformin, sulfonylurea, thiazolidinedione (TZD), insulin, and any other drug. In addition to improving glucose control, DPP-4 inhibitors have also shown a neutral effect on weight gain, improved beta-cell function, and lowered the risk of hypoglycemia. Because of these advantages, DPP-4 inhibitors are widely used in the treatment of all patients with type 2 diabetes mellitus, but especially elderly patients. Therefore, more information regarding these strengths of DPP-4 inhibitors will lead to better treatment of patients with T2DM.

Keyword

Dipeptidylpeptidase-4 inhibitors; Type 2 diabetes mellitus; Efficacy; Safety

MeSH Terms

Aged
Diabetes Mellitus, Type 2
Glucose
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Metformin
Thiazolidinediones
Weight Gain
Glucose
Hypoglycemic Agents
Insulin
Metformin
Thiazolidinediones
Full Text Links
  • JKD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error